Loading...
Please wait, while we are loading the content...
Similar Documents
Method of Treating Atrophic Vaginitis
| Content Provider | The Lens |
|---|---|
| Abstract | The present invention provides novel pharmaceutical compositions containing triphenylethylene derivative compounds, and methods of using the composition for treatment of symptoms associated with atrophic vaginitis. The pharmaceutical compositions are prepared for the vaginal administration of triphenylethylene derivative compounds in single or combination therapies. Preferably, the triphenylethylene derivative is tamoxifen. |
| Related Links | https://www.lens.org/lens/patent/011-826-702-204-914/frontpage |
| Language | English |
| Publisher Date | 2017-06-13 |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Patent |
| Jurisdiction | United States of America |
| Date Applied | 2008-06-27 |
| Agent | Wilmer Cutler Pickering Hale and Dorr Llp |
| Applicant | Klamerus Bernadette Chollet Janet A Mermelstein Fred |
| Application No. | 16333408 |
| Claim | A method of treating symptoms of atrophic vaginitis in a patient in need thereof, the method comprising vaginally administering a composition consisting essentially of an effective amount of 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers to a hysterectomized patient daily for an initial multi-day period of time, followed by administering the composition less frequently on nonconsecutive days as part of a maintenance therapy regimen. A method of treating symptoms of atrophic vaginitis in a patient in need thereof, the method comprising vaginally administering a composition consisting essentially of a therapeutically effective amount of 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof and a progesterone compound and one or more pharmaceutically acceptable carriers to a non-hysterectomized patient daily for an initial multi-day period of time, followed by administering the composition less frequently on nonconsecutive days as part of a maintenance therapy regimen. The method of claim 1 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate). The method of claim 2 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate). The method of claim 2 , wherein the progesterone is micronized progesterone. The method of claim 2 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate) and the progesterone is micronized progesterone. The method of claim 1 , wherein the therapeutically effective amount of 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is effective to reduce the incidence of thrombogenic events associated with oral therapy. The method of claim 1 , wherein the therapeutically effective amount of 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is effective to reduce the incidence of a worsening of climacteric symptom associated with an oral therapy. The method according to claim 2 , wherein the therapeutically effective amount of the progesterone is effective to produce an anti-proliferative effect on the endometrium. The method of claim 6 , wherein (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate) is in an amount of about 20 mg, and the micronized progesterone is in an amount of about 15 mg, and wherein the composition has an antiproliferative effect on an endometrium. The method of claim 6 , wherein (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate) is in an amount of about 10 mg, and the micronized progesterone is in an amount of about 7.5 mg, and wherein the composition has an antiproliferative effect on an endometrium. The method of claim 6 , wherein (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N, N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate) is in an amount of about 30 mg, and the micronized progesterone is in an amount of about 30 mg, and wherein the composition has an antiproliferative effect on an endometrium. The method of claim 1 , wherein the composition is administered for at least 3 months. The method of claim 1 , wherein the composition is administered during the maintenance therapy regimen for at least 12 months. The method of claim 1 , wherein the composition is administered during the maintenance therapy regimen at least one time per week. The method of claim 1 , wherein the composition is administered during the maintenance therapy regimen at least two times per week. The method of claim 1 , wherein the composition is administered during the maintenance therapy regimen at least three times per week. The method according to claim 1 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is administered as a vaginal suppository. The method of claim 1 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is administered as a vaginal cream. The method of claim 2 , wherein the composition is administered during the maintenance therapy regimen for at least 3 months. The method of claim 2 , wherein the composition is administered during the maintenance therapy regimen for at least 12 months. The method of claim 2 , wherein the composition is administered during the maintenance therapy regimen at least one time per week. The method of claim 2 , wherein the composition is administered during the maintenance therapy regimen at least two times per week. The method of claim 2 , wherein the composition is administered during the maintenance therapy regimen at least three times per week. The method according to claim 2 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is administered as a vaginal suppository. The method of claim 2 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is administered as a vaginal cream. A method of treating menopause symptoms, the method comprising vaginally administering a suppository comprising: a) about 0.2 mg to about 200 mg of 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof; and b) about 1.0 g to about 2.0 g of a fatty acid base; and c) about 0.01 g to about 0.02 g silica gel, the method further comprising administering the suppository daily for an initial multi-day period of time, followed by administering the suppository less frequently on nonconsecutive days as part of a maintenance therapy regimen. The method of claim 27 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate). A method of treating menopause symptoms, the method comprising vaginally administering an effective amount of a cream comprising: a) about 0.2 mg to about 200 mg of 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof, b) about 0.5 g to about 2.0 g emollient cream; c) about 0.025 mL to about 0.05 mL propylene glycol; and d) about 0.01 g to about 0.02 g silica gel, the method further comprising administering the cream daily for an initial multi-day period of time, followed by administering the cream less frequently on nonconsecutive days as part of a maintenance therapy regimen. The method of claim 29 , wherein 1-(p-dimethylamino-ethoxphenyl)-2-ethyl-1,2-diphenylethylene (tamoxifen) or a non-toxic pharmaceutically acceptable salt thereof is (Z) 2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (tamoxifen citrate). The method of claim 29 , wherein the cream further comprises Vitamin E. |
| CPC Classification | Preparations For Medical; Dental Or Toiletry Purposes Specific Therapeutic Activity Of Chemical Compounds Or Medicinal Preparations |
| Examiner | Melissa Fisher |
| Extended Family | 060-542-705-394-664 117-693-365-014-470 073-475-696-966-265 122-151-263-604-183 178-821-450-169-916 047-728-008-660-60X 140-490-125-031-638 106-416-579-097-65X 036-334-263-757-264 111-872-551-966-913 042-003-395-464-982 115-625-653-396-373 015-829-109-659-503 141-778-652-742-182 124-632-217-341-327 011-826-702-204-914 |
| Patent ID | 9675546 |
| Inventor/Author | Klamerus Bernadette Chollet Janet A Mermelstein Fred |
| IPC | A61K9/02 A61K9/00 A61K31/215 A61K31/56 A61K31/57 A61K47/02 A61K47/14 A61K47/22 A61P5/24 A61P15/02 |
| Status | Active |
| Simple Family | 060-542-705-394-664 117-693-365-014-470 073-475-696-966-265 178-821-450-169-916 122-151-263-604-183 047-728-008-660-60X 140-490-125-031-638 106-416-579-097-65X 036-334-263-757-264 111-872-551-966-913 042-003-395-464-982 011-826-702-204-914 141-778-652-742-182 124-632-217-341-327 015-829-109-659-503 |
| CPC (with Group) | A61K9/0034 A61K9/02 A61K31/215 A61K31/56 A61K31/57 A61K47/02 A61K47/14 A61K47/22 A61P5/24 A61P15/02 A61P29/00 A61P43/00 A61K31/138 |
| Issuing Authority | United States Patent and Trademark Office (USPTO) |
| Kind | Patent/New European patent specification (amended specification after opposition procedure) |
